{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-239127","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.343292+00:00","generated_at":"2026-06-10T10:58:47.440065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Benitec Biopharma reports FY2023 net loss of $19.6M; FDA cleared BB-301 IND; completed $30.9M offering","bullets":["Net loss $19.6M ($14.12/share) vs $18.2M ($37.88/share) prior year; cash $2.5M at June 30, 2023.","FDA cleared IND for BB-301 for OPMD in June 2023; 15 subjects enrolled in Natural History Study as of September.","Closed $30.9M public offering in August 2023 to fund BB-301 clinical development and operations.","R&D expenses $12.8M (up from $11.3M); expect to dose first BB-301 patient in 2H2023 with interim data in 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-239127","json":"https://secwatch.observer/filing/0001193125-23-239127.json","markdown":"https://secwatch.observer/filing/0001193125-23-239127.md","text":"https://secwatch.observer/filing/0001193125-23-239127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/0001193125-23-239127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/d498664d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:58:47.440065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b544d4a3321d822c404798bdb10ae2664d45437e","claim":"Benitec Biopharma Inc. reported financial results for the fiscal year ended June 30, 2023.","evidence_excerpt":"On September 21, 2023, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal year ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/0001193125-23-239127-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}